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Objective: To study the effect of Runing II (a Chinese herbal preparation for mammary cancer) on the 
growth and metastasis of transplanted tumor of mammary cancer MA-891-bearing TA2 mice and its 
mechanism. Methods: The model of mammary cancer MA-891 cell strain transplanted tumor of TA2 mice 
with lung metastasis were developed to observe the effect of Runing II on the growth and metastasis of the 
transplanted tumor. The immunohistochemical method and image analysis were adopted to detect the levels 
of vascular endothelial growth factor (VEGF), vascular endothelial growth factor receptor (VEGFR), and 
micro-vessel count (MVC) and micro-vessel area (MVA). Results: In the Runing II group, the tumor weight 
inhibition rate and the lung metastasis inhibition rate were 37.3% and 65.4% respectively, the tumor growth 
and lung metastasis were obviously inhibited; And the levels of VEGF and VEGFR, MVC and MVA were 
significantly decreased as compared with those in the tumor-bearing control group (P<0.05). Conclusion: 
The Chinese herbal preparation Running II can inhibit the metastasis of tumor through inhibiting the 
angiogenesis, and the mechanism is possibly related with down-regulation of VEGF and VEGFR expression.
 Key words: mammary tumor; angiogenesis; vascular endothelial growth factor (VEGF); Runing II (a Chinese 
herbal preparation for mammary cancer) 
Mammary cancer is a malignant tumor severely 
threatening female health and the disease incidence 
ranks the first in the female malignant tumors, with a 
tendency to increase year by year. Although its 
therapeutic methods have made some advances, the 
long-term survival rate for the patient of mammary 
cancer has not been obviously raised because of the 
invasive growth and metastasis of tumor. The 
angiogenesis of tumor is a basic condition for growth, 
invasion and metastasis of tumor. Therefore, 
inhibition of angiogenesis of tumor is an effective 
way for preventing production and development of 
tumor, and prolonging life of the patient.1 In the 
present study, the mechanism of Chinese drug 
Runing II with functions of supplementing qi and 
nourishing yin, regulating thoroughfare and 
conception vessels, resolving mass and detoxicating 
in inhibiting tumor and anti-metastasis was studied 
from angiogenesis and its regulatory factors in the 
transplanted tumor of mammary cancer MA-891 of 
TA2 mice with lung metastasis. 
MATERIALS 
Sixty SPF female TA2 mice, weighing (20±2) g, aged 
6-8 weeks, were purchased from the Department of 
Laboratory Animals, Tianjin University of Medical 
Sciences. Mammary cancer MA-891 cell strain of the 
mouse was supplied by Prof. Luo Liqin, the 
Pathological Laboratory, Institute of Tumor, Chinese 
Academy of Medical Sciences. 
Runing II is composed of Sheng Huang Qi (⫳咘㡾
Radix Astragali Mongolici), Shan Ci Gu (ቅ᜜㦛
Pseudobulbus Cremastrae), Tai Zi Shen (໾ᄤখ
Radix Pseudostellariae), Gou Qi Zi (ᶌᴲᄤ Fructus 
Lycii), E Zhu (㥾ᴃ Rhizoma Curcumae Phaeocaulis), 
Yi Yi Ren (㭣㢵ҕ Semen Coicis), Yin Yang Huo (⎿
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㕞㯓 Herba Epimedii), Dang Gui (ᔧᔦ Radix 
Angelicae Sinensis), etc., with dose ratio of 1.67: 
1.67: 1.33: 1.33: 1.33: 1.33: 1.33: 1, which were 
prepared a decoction by the Section of Pharmaceutics, 
Longhua Hospital, according to traditional technique, 
and kept at 4ć for use; Cyclophosphamide (CTX, 
200mg/ampule, branch number: 981104) and 
tamoxifen (TAM) were produced by Shanghai 
Hualian Pharmaceutical Co. Ltd.; Normal saline was 
produced by Shanghai Fumin Pharmaceutical Co.  
Vascular endothelial growth factor (VEGF) 
polyclonal antibody (working dilutions 1:25–1:50), 
vascular endothelial growth factor receptor (VEGFR, 
working dilutions 1:30–1:50), and FVIIIAg 
polyclonal antibody (working dilution 1:50) were 
purchased from Santa Cruz Biotechnology Inc; 
EnVision second antibody, rabbit anti-rat VEGF 
antibody, goat anti-rabbit FVIII Ag antibody and goat 
anti-rabbit VEGFR antibody, and EnVision Kit were 
purchased from Dako Co., Denmark; 3,3- 
Diaminobenzidine (DAB) was purchased from 
Shanghai Huamei Bioengineering Factory.   
METHODS 
Developing of animal model 
Animal model was developed with inference to the 
methods of Luo and Gao, et al.2,3. In vitro cultured 
mammary cancer MA-891 cells of the mouse at a 
logarithmic survive phase were selected and the 
concentration of cell was regulated as 1x107/ml. 
Under aseptic condition the mammalian cancer cells 
were inoculated into the TA2 mice subcutaneous part 
of the right axilla (0.2 ml/mouse, i.e. 2X106 cells/ 
mouse).  
Grouping of animals and methods of 
administration 
Two days after inoculation, the mice were randomly 
divided into 4 groups, 15 mice in each group. 1) 
Tumor-bearing control group: 0.4 ml normal saline 
was administrated intragastrically, once each day, five 
times each week. 2) Runing II group: Runing II was 
diluted with normal saline and 0.4 ml of this dilution 
corresponding to 48 g·kg-1·d-1 which was calculated 
according to the attached table   “Conversion Table 
between Human and Animal Body Surface Areas” in 
“ Methodology of Studies on pharmacology of 
Chinese Drugs”4 was given intragastrically, once 
daily, five times each week. 3) CTX control group: In 
reference with the dosage used by Jiang Bo,5 CTX 
was diluted with normal saline and 0.4 ml 
corresponding to 50 mg·kg-1·d-1 was given intra- 
gastrically, once every other day, thrice each week. 4) 
TAM control group: TAM was diluted with normal 
saline and 0.4 ml corresponding to 2.7 mg·kg-1·d-1
was administrated intragastrically, once daily, five 
times each week. The drugs were given for 3 weeks 
in all the four groups. 
Sampling 
At the 22nd day after administration, the mice were 
sacrificed by dislocation of cervical vertebrae, and 
weighed. Then the tumor mass and the lung were 
taken and weighed respectively. The real body weight 
of the mouse = the body weight weighted – the tumor 
weight. Grey nodes on the lung surface, i.e., 
metastasis focuses, were counted by naked eyes. The 
tumor mass was placed into 10% neutral 
formaldehyde solution for fixation, followed by 
paraffin embedding, ultrathin sectioning, immune- 
ohistochemical Envision two-step straining, and 
determination of VEGF, VEGFR, microvessel count 
(MVC) and microvessel area (MVA). 
The tumor weight inhibition rate 
The tumor inhibition rate = (mean tumor weight of 
the control group after treatment – mean tumor 
weight of the medication group after treatment)/mean 
tumor weight of the control group after treatment ×
100%. 
The lung metastasis inhibition rate 
The lung metastasis inhibition rate = (mean lung 
metastasis node number of the control group – mean 
lung metastasis node number of the medication 
group)/mean lung metastasis node number of the 
control group x 100%. 
Immunohistochemical Envision two-step staining 
The paraffin section of 4 μm was taken, followed by 
routine deparaffin with xylene, gradient dehydration, 
washing with PBS, 5 min x 3 times; the section was 
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immerged in 0.01 mol/L, pH6.0 citrate buffer, put in 
a microwave oven of 98ć for 10 min for antigenic 
repair and naturally cooled at room temperature after 
taking from the microwave oven; dripping the first 
antibody (above-mentioned antibody and dilution of 
corresponding antibody respectively), 37ć, 90 min, 
washing with PBS, 5 min x 3 times; dripping 
Envasion second antibody, at room temperature for 
60 min, washing with PBS, 5 min x 3 times; dripping 
newly prepared DAB color-developing solution, 
controlling developing color for 3–10 min under a 
microscope, counterstaining for 45 s with campeachy, 
rinsing with tap water, drying with a blower, 
mounting with neutral gum. The cell with the 
cytoplasm of brown-yellow or black brown granules 
was regarded as positive. The known positive section 
of mammary cancer was used as positive control, and 
that in which PBS buffer substituted for the first 
antibody was used as negative control.  
Image analysis 
ACE video camera (resolving power 930 lines) and 
LEICAQ500W image analyzer and LEICA full- 
automatic image analysis system were used. Under a 
microscope x 200, 2 vision fields in each section 
were randomly selected for determination of VEGF 
or 3 vision fields for determination of VEGFR and 
MVA, and the percentage of positive area to whole 
vision field area were calculated in all of the groups. 
For determination of MVC, 5 regions with the richest 
blood vessels were selected in each section under a 
microscope x 100, and then under x 400 the 
micro-vessels in each vision field of 5 no-overlapping 
regions were counted, and the mean was used as 
average micro-vessel counter (MVC) of the tumor. 
Statistical method 
Software SPSS8.0 was used and chi-square test was 
used for comparison between the rates, and t-test or 
one-way ANOVA was used for comparison of means. 
RESULTS 
Tumor-inhibiting and anti-metastasis effects of 
Running II on the transplanted tumor of 
mammary cancer MA-891-bearing TA2 mice with 
lung metastasis 
It was showed in Table 1 that the tumor weight 
inhibition rate was 37.3% in the Runing II group and 
86.2% in the CTX control group, both tumor 
inhibition rates being >30%, with significant 
difference (both P<0.05) as compared with both 
tumor-bearing control group and TAM control group, 
indicating that both Runing II and CTX have a 
certain tumor-inhibiting effect. And there was a 
significant difference (P<0.05) between Runing II 
group and CTX control group in the tumor inhibition 
rate, indicating that the tumor-inhibiting effect of 
Runing II was lower than that of CTX. The lung 
metastasis inhibition rate was 65.4% in the Runing II 
group and 43.9% in the CTX control group, with 
significant difference (both P<0.05) as compared 
with tumor-bearing control group and TAM control 
group, indicating that both Runing II and CTX have a 
certain tumor metastasis-inhibiting action. And there 
was a significant difference between Runing II group 
and CTX control group (P<0.05) in the lung 
metastasis inhibition rate, suggesting that the 
anti-metastasis action of Runing II is superior to that 
of CTX. 
Table 1. Comparison of tumor-inhibiting and anti-metastasis effects of Runing II on the transplanted tumor in 
mammary cancer MA-891-bearing mince ( x ±s)
Group n Tumor weight  
(g) 
Tumor inhibition rate 
(%) 
Number of lung metastasis 
focus 
Metastasis inhibition 
rate (%) 
Tumor-bearing control 10 3.45±1.27 – 12.70±2.41 – 
Runing II   10    2.16±1.50ǻ # *  37.3%ǻ # *     4.40±1.58ǻ # *  65.4%ǻ # * 
CTX control 8   0.48±0.22ǻ* 86.2%ǻ*    7.13±3.23ǻ* 43.9%ǻ* 
TAM control 9 5.47±2.20 – 12.22±3.15 – 
Notes: Compared with the tumor-bearing group, ǻP<0.05; Compared with the CTX control group, #P<0.05; Compared with the TAM 
control group, *P<0.05. 
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Effects of Runing II on VEGF and VEGFR 
expressions in the transplanted tumor of MA-891- 
bearing TA2 mice 
As shown in Table 2, the expressions of VEGF and 
VEGFR in both Runing II group and CTX control 
group were significantly lower than those in the 
tumor-bearing control group (P<0.05), with 
significant difference between the two. In the Runing 
II group, the VEGF and VEGFR expressions were 
not significantly different from those in the CTX 
control group (P>0.05), the VEGF expression was 
significantly lower than that in the TAM control 
group (P<0.05), and the VEGFR expression was 
similar to that in the TAM control group (P>0.05). In 
the CTX control group, the VEGF and VEGFR 
expression was lower than those in the TAM control 
group. In the TAM control group, the VEGF 
expressions were similar to that in the tumor-bearing 
control group (P>0.05), and the VEGFR expression 
was lower than that in the tumor-bearing control 
group (P<0.05).  
Effect of Runing II on MVA and MVC of the 
transplanted tumor in MA-891-bearing TA2 mice 
As shown in Table 3, the levels of MVA and MVC in 
the transplanted cancer in the medication groups were 
significantly lower than those in the tumor-bearing 
control group (P<0.05); in the Runing II group, the 
levels of MVA and MVC were significantly higher 
than those in the CTX control group (P<0.05), the 
level of MVC was lower than that in the TAM control 
group (P<0.05), and the MVA level was similar to 
that in the TAM control group (P>0.05).
  Table 2. Comparison of VEGF and VEGFR expressions in the transplanted tumor of MA-891-bearing 
TA2 mice in the groups (%, x ±s)
Group VEGF (%) VEGFR (%) 
Tumor-bearing control   20.3±7.9 (7) 14.64±3.67 (8)
Runing II   13.7±6.4 (8) ǻ*   7.90±3.88 (8) ǻ
CTX control   13.6±5.4 (7) ǻ*    5.93±5.23 (6) ǻ* 
CTM control    25.7±10.0 (9) #   10.19±4.16 (7) ǻ#
Notes: Compared with the tumor-bearing group, ǻP<0.05; Compared with the CTX control group, #P<0.05;  
Compared with the TAM control group, *P<0.05. Sample number showed in the brackets. 
Table 3. Comparison of MVC and MVA in transplanted tumor of MA-891-bearing mice in the groups (%, x ±s) 
Groups MVC (%) MVA (%) 
Tumor-carrying control 37.73±10.26 (8) 15.08±1.12 (8) 
Runing II   16.00±2.78 (9)ǻ # *     6.68±2.13 (8)ǻ # *
CTX control  9.21±3.53 (5)ǻ   4.87±2.23 (6)ǻ
TAM control   26.83±11.77 (8)ǻ #   10.59±2.93 (7)ǻ #
Notes: Compared with the tumor-bearing group, ǻP<0.05; Compared with the CTX control group, #P<0.05; Compared with the 
TAM control group, *P<0.05. Sample number showed in the brackets. 
DISCUSSION 
Traditional Chinese medicine holds that genesis and 
development of tumor result from comprehensive 
effects of endopathic and exopathic factors but with 
the stress on the former. In previous clinical study, 
Prof. Lu and Tang held that vital-qi deficiency in the 
interior and disharmony of thoroughfare and 
conception vessels are main causes of tumor genesis, 
and internal invasion, moving and spreading of 
cancer pathogens are main conditions of growth and 
metastasis of mammary cancer.6 Therefore, in 
treatment, they advocate that nourishing vital qi and 
removing masses. Runing II is a Chinese herbal 
formula which is summed up through clinical 
practice of many years according to the treatment 
principle of strengthening the body resistance first 
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and eliminating pathogenic factors second. In the 
formula, Sheng Huang Qi (⫳咘㡾 Radix Astragali 
Mongolici), Tai Zi Shen ( ໾ ᄤ খ Radix 
Pseudostellariae), Gou Qi Zi (ᶌᴲᄤ Fructus Lycii), 
Yin Yang Huo (⎿㕞㯓 Herba Epimedii) are 
sovereign ingredients, with effects of supplementing 
qi and nourishing yin, regulating thoroughfare and 
conception vessels, which conforms to commonly- 
seen characteristics of mammary cancer such as both 
qi and yin deficiency and disharmony of thoroughfare 
and conception vessels. Clinically, this formula 
achieves obvious effect of prolonging survival time, 
increasing quality of life, stabilizing tumor focus and 
preventing metastasis of cancer. 
The present study established the model of mammary 
cancer MA-891 cell strain transplanted tumor of TA2 
mice with lung metastasis and observed the effect of 
Runing II on solid tumor growth and lung metastasis, 
and found that there were significant differences in 
the tumor inhibition rate and the lung metastasis 
inhibition rate between the Runing II group and the 
tumor-bearing group, and between the Runing II 
group and the CTX control group, showing that 
Runing II has obvious functions of inhibiting tumor 
growth and anti-metastasis. Additionally, tamoxifen 
(TAM) does not have obvious function of inhibiting 
tumor growth and anti-metastasis in the model mice, 
being similar to the result that mammary cancer 
MA-891 is ER-cell strain and the report about direct 
action of low concentration of TAM abroad.7
Tumor is a typical blood vessel dependent disease, 
and its growth, infiltration and metastasis depend on 
angiogenesis. At the same time, the neova- 
scularization again supply a metastasis channel for 
tumor cells, creating the favorable conditions for 
growth, metastasis and diffusion of tumor. 8, 9 VEGF 
is a pro-angiogenic factor with the strongest, unique 
and specific action on vascular endothelial cells, and 
many tumor cells can secrete VEGF, which increases 
vascular permeability and directly act on vascular 
endothelial cells through binding to VEGF receptor, 
stimulating its division and proliferation, inducing 
angiogenesis of tumor and influencing micro-vessel 
number, so as to promote growth and metastasis of 
tumor.10,11 Most tumor cells have high VEGF 
expression, while in the normal tissues, only a small 
number of organs such as kidney, ovary, etc., have 
higher VEGF expression. Therefore, some scholars 
hold that VEGF can be used as markers of tumor 
metabolism and metastasis12 and more ideal target 
part of blocking neoangiogenesis in tumor,13 and 
interfering vascular regulatory factor of tumor and its 
acting link, regulating expression of angiogenesis 
factors, and inhibiting angiogenesis possibly control 
growth and metastasis of tumor. 
The results in the present study indicate that Runing 
II can down-regulate expressions of VEGF and 
VEGFR to possibly block signal conduction of 
VEGF-induced migration and proliferation of 
endothelial cells, and further inhibit angiogenesis in 
tumor, hence exerting antineoplastic and anti- 
metastasizing effects. 
Previous studies showed that in the growth course of 
malignant tumor, over fast growth of the tissue 
inevitably induced serious anoxia of local tissue, and 
anoxia could stimulate synthesis of VEGF mRNA 
and slow down degradation of VEGF mRNA to 
induce genesis of a great number of local new 
capillary vessels.14,15 In observation of immune- 
ohistochemical positive staining cells, the authors
found obvious VEGF expression in the cytoplasm of 
dying necrotic tumor cells, on the contrary, less or no 
expression of VEGF in tumor cells with active 
proliferation, which may be related with higher level 
of anoxia inducing factor in tumor cells, conforming 
to the report of Talks KL, et al.16 Runing II contains 
Dang Gui (ᔧᔦ Radix Angelicae Sinensis), E Zhu 
(㥾ᴃ Rhizoma Curcumae Phaeocaulis), Sheng Yi Yi 
Ren (⫳㭣㢵ҕ Semen Coicis), Shan Ci Gu (ቅ᜜㦛
Pseudobulbus Cremastrae), etc., which function 
activating blood circulation, resolving phlegm and 
removing turbid. They inhibit synthesis and secretion 
of VEGF possibly through improving local 
microcirculation of tumor, increasing oxygen supply 
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to tumor cells, hence inhibiting growth of tumor to 
perform anti-metastasis. 
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